<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is characterized by cytopenia, mainly <z:hpo ids='HP_0001903'>anemia</z:hpo>, because of ineffective hematopoiesis </plain></SENT>
<SENT sid="1" pm="."><plain>Some of the patients with <z:hpo ids='HP_0010972'>ineffective erythropoiesis</z:hpo>, with or without ring sideroblasts in their bone marrow, develop severe <z:hpo ids='HP_0001903'>anemia</z:hpo> requiring frequent blood transfusions and consequently develop <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Excess free iron in cells catalyses the generation of reactive oxygen species (ROS) that cause <z:mpath ids='MPATH_1'>cell and tissue damage</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>Using flow cytometry techniques, we compared the oxidative status of red blood cells (RBC), platelets and neutrophils in 14 MDS patients with those of <z:mpath ids='MPATH_458'>normal</z:mpath> donors </plain></SENT>
<SENT sid="4" pm="."><plain>The results show that ROS were higher while reduced <z:chebi fb="0" ids="16856">glutathione</z:chebi> (GSH) was lower in their RBC and platelets compared with <z:mpath ids='MPATH_458'>normal</z:mpath> cells </plain></SENT>
<SENT sid="5" pm="."><plain>In neutrophils, no difference was found in ROS, while the GSH levels were lower </plain></SENT>
<SENT sid="6" pm="."><plain>A correlation (r = 0.6) was found between serum ferritin levels of the patients and the ROS in their RBC and platelets </plain></SENT>
<SENT sid="7" pm="."><plain>The <z:mp ids='MP_0003674'>oxidative stress</z:mp> was ameliorated by a short incubation with the iron-<z:chebi fb="0" ids="38161">chelators</z:chebi>, the <z:chebi fb="0" ids="4356">deferrioxamine</z:chebi> and deferiprone or with <z:chebi fb="11" ids="22586">antioxidants</z:chebi> such as <z:chebi fb="0" ids="28939">N-acetylcysteine</z:chebi>, suggesting that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients might benefit from treatment with iron-<z:chebi fb="0" ids="38161">chelators</z:chebi> and <z:chebi fb="11" ids="22586">antioxidants</z:chebi> </plain></SENT>
</text></document>